DXCM

DexCom’s G7 continuous glucose monitor (CGM) results from the CONNECT trial were published in the New England Journal of Medicine, highlighting significant glycemic benefits for non‑insulin Type 2 diabetes patients. The NEJM release has drawn attention to the company’s clinical data and potential market impact.

On October 21, 2026, DexCom shares fell 6.22% as part of the S&P 500’s list of top losers. The drop reflects broader market movements and investor sentiment on the day.

The CONNECT study shows DexCom’s G7 CGM improves A1C levels and glucose control in non‑insulin Type 2 diabetes patients. These results support wider adoption of CGM technology among this group.

DexCom’s 15‑day G7 sensor reduces CGM costs, potentially boosting margins ahead of a broader Type 2 diabetes market expansion. The cost advantage is highlighted in the company’s outlook.

SAN DIEGO, October 14, 2026--DexCom, Inc.

The NEJM publication of DexCom’s CONNECT study marks the first clinical data on standalone real‑time CGM in nearly two decades, emphasizing benefits for all Type 2 patients, including those over 65. The findings support earlier CGM use in diabetes care.

DexCom’s strong margins, 15‑day G7 rollout, and promising pipeline underpin its growth outlook, suggesting it remains a solid holding. However, factory ramp‑up costs, currency swings, and input price pressures pose potential risks.